Celularity Secures Up to $12M in Funding

Dow Jones12-19

By Katherine Hamilton

Celularity entered into two binding term sheets for a senior secured term loan and a secured convertible note, adding up to $12 million in new financing.

The cellular medicine company said Thursday it expects initial proceeds of $10 million with the availability of additional funding up to $2 million subject to certain conditions.

The funding is from Philip Barach, the co-founder and former president of DoubleLine Capital, a Los Angeles investment-management firm.

The senior secured term loan has a stated principal amount of $7 million.

The convertible notes provide for aggregate commitments of up to $5 million, issuable in multiple tranches. They are convertible into shares of Celularity's Class A stock at a conversion price of $1.66 a share.

In connection with the transactions, Celularity has agreed to issue warrants to purchase shares of its Class A common stock equal to 33% of the as-converted principal amount. The warrants will become exercisable six months after the issuance and have an exercise price of $2 a share.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 18, 2025 14:33 ET (19:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592186706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 03:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592186706","market":"sh","top_or_hot":-1,"title":"Celularity Secures Up to $12M in Funding","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celularity entered into two binding term sheets for a senior secured term loan and a secured convertible note, adding up to $12 million in new financing. \n</p>\n<p>\n  The cellular medicine company said Thursday it expects initial proceeds of $10 million with the availability of additional funding up to $2 million subject to certain conditions. \n</p>\n<p>\n  The funding is from Philip Barach, the co-founder and former president of DoubleLine Capital, a Los Angeles investment-management firm. \n</p>\n<p>\n  The senior secured term loan has a stated principal amount of $7 million. \n</p>\n<p>\n  The convertible notes provide for aggregate commitments of up to $5 million, issuable in multiple tranches. They are convertible into shares of Celularity's Class A stock at a conversion price of $1.66 a share. \n</p>\n<p>\n  In connection with the transactions, Celularity has agreed to issue warrants to purchase shares of its Class A common stock equal to 33% of the as-converted principal amount. The warrants will become exercisable six months after the issuance and have an exercise price of $2 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2025 14:33 ET (19:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celularity Secures Up to $12M in Funding</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelularity Secures Up to $12M in Funding\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-19 03:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celularity entered into two binding term sheets for a senior secured term loan and a secured convertible note, adding up to $12 million in new financing. \n</p>\n<p>\n  The cellular medicine company said Thursday it expects initial proceeds of $10 million with the availability of additional funding up to $2 million subject to certain conditions. \n</p>\n<p>\n  The funding is from Philip Barach, the co-founder and former president of DoubleLine Capital, a Los Angeles investment-management firm. \n</p>\n<p>\n  The senior secured term loan has a stated principal amount of $7 million. \n</p>\n<p>\n  The convertible notes provide for aggregate commitments of up to $5 million, issuable in multiple tranches. They are convertible into shares of Celularity's Class A stock at a conversion price of $1.66 a share. \n</p>\n<p>\n  In connection with the transactions, Celularity has agreed to issue warrants to purchase shares of its Class A common stock equal to 33% of the as-converted principal amount. The warrants will become exercisable six months after the issuance and have an exercise price of $2 a share. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 18, 2025 14:33 ET (19:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592186706","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592186706","pubTimestamp":1766086380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Celularity entered into two binding term sheets for a senior secured term loan and a secured convertible note, adding up to $12 million in new financing.The cellular medicine company said Thursday it expects initial proceeds of $10 million with the availability of additional funding up to $2 million subject to certain conditions.The funding is from Philip Barach, the co-founder and former president of DoubleLine Capital, a Los Angeles investment-management firm.The senior secured term loan has a stated principal amount of $7 million.The convertible notes provide for aggregate commitments of up to $5 million, issuable in multiple tranches. They are convertible into shares of Celularity's Class A stock at a conversion price of $1.66 a share.In connection with the transactions, Celularity has agreed to issue warrants to purchase shares of its Class A common stock equal to 33% of the as-converted principal amount. The warrants will become exercisable six months after the issuance and have ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CELU":"Celularity Inc."},"translate_title":"Celularity获得高达1200万美元的资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELU":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Celularity entered into two binding term sheets for a senior secured term loan and a secured convertible note, adding up to $12 million in new financing. \n\n\n  The cellular medicine company said Thursday it expects initial proceeds of $10 million with the availability of additional funding up to $2 million subject to certain conditions. \n\n\n  The funding is from Philip Barach, the co-founder and former president of DoubleLine Capital, a Los Angeles investment-management firm. \n\n\n  The senior secured term loan has a stated principal amount of $7 million. \n\n\n  The convertible notes provide for aggregate commitments of up to $5 million, issuable in multiple tranches. They are convertible into shares of Celularity's Class A stock at a conversion price of $1.66 a share. \n\n\n  In connection with the transactions, Celularity has agreed to issue warrants to purchase shares of its Class A common stock equal to 33% of the as-converted principal amount. The warrants will become exercisable six months after the issuance and have an exercise price of $2 a share. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 14:33 ET (19:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592186706","isCrawlerRequest":true}